SIRPA and neoplasm: These results also suggested that both enhanced expression of CD47 in tumor cells and upregulated SIRPα in tumor-associated macrophages plays a role in tumor immune evasion and that disrupting CD47 upregulation is effective for sensitizing doxorubicin treatment.